Annual report

Period2024-01-01 → 2024-12-31

Filed2025-03-28

StandardIFRS

ConsolidatedYes

Data checks21 of 21 passed

Key figures · 148

Metric	Value	Period	Scope	Source row
Revenue	¥2.34T	2024-01-01 → 2024-12-31	Cons.	Revenue IFRS
Revenue	¥2.13T	2023-01-01 → 2023-12-31	Cons.	Revenue IFRS
Revenue	¥1.99T	2022-01-01 → 2022-12-31^d	Cons.	Revenue IFRS (5-year summary)
Revenue	¥1.82T	2021-01-01 → 2021-12-31^d	Cons.	Revenue IFRS (5-year summary)
Revenue	¥1.85T	2020-01-01 → 2020-12-31^d	Cons.	Revenue IFRS (5-year summary)
Operating income	¥125.3bn	2024-01-01 → 2024-12-31	Cons.	Operating profit loss IFRS
Operating income	¥150.3bn	2023-01-01 → 2023-12-31	Cons.	Operating profit loss IFRS
Profit before tax	¥139.7bn	2024-01-01 → 2024-12-31	Cons.	Profit loss before tax IFRS
Profit before tax	¥197.0bn	2023-01-01 → 2023-12-31	Cons.	Profit loss before tax IFRS
Profit before tax	¥191.4bn	2022-01-01 → 2022-12-31^d	Cons.	Profit loss before tax IFRS (5-year summary)
Profit before tax	¥99.6bn	2021-01-01 → 2021-12-31^d	Cons.	Profit loss before tax IFRS (5-year summary)
Profit before tax	¥124.5bn	2020-01-01 → 2020-12-31^d	Cons.	Profit loss before tax IFRS (5-year summary)
Net income (owners)	¥58.2bn	2024-01-01 → 2024-12-31	Cons.	Profit loss attributable to owners of parent IFRS
Net income (owners)	¥112.7bn	2023-01-01 → 2023-12-31	Cons.	Profit loss attributable to owners of parent IFRS
Net income (owners)	¥111.0bn	2022-01-01 → 2022-12-31^d	Cons.	Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)	¥59.8bn	2021-01-01 → 2021-12-31^d	Cons.	Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)	¥71.9bn	2020-01-01 → 2020-12-31^d	Cons.	Profit loss attributable to owners of parent IFRS (5-year summary)
Net income	¥85.8bn	2024-01-01 → 2024-12-31	Cons.	Profit loss IFRS
Net income	¥150.4bn	2023-01-01 → 2023-12-31	Cons.	Profit loss IFRS
Total assets	¥3.35T	at 2024-12-31	Cons.	Assets IFRS
Total assets	¥2.87T	at 2023-12-31	Cons.	Assets IFRS
Total assets	¥2.54T	at 2022-12-31^d	Cons.	Total assets IFRS (5-year summary)
Total assets	¥2.47T	at 2021-12-31^d	Cons.	Total assets IFRS (5-year summary)
Total assets	¥2.46T	at 2020-12-31^d	Cons.	Total assets IFRS (5-year summary)
Total liabilities	¥1.82T	at 2024-12-31	Cons.	Liabilities IFRS
Total liabilities	¥1.44T	at 2023-12-31	Cons.	Liabilities IFRS
Net assets / equity	¥1.53T	at 2024-12-31	Cons.	Equity IFRS
Net assets / equity	¥1.43T	at 2023-12-31	Cons.	Equity IFRS
Net assets / equity	¥1.25T	at 2022-12-31^d	Cons.	Equity IFRS
Equity (owners)	¥1.18T	at 2024-12-31	Cons.	Equity attributable to owners of parent IFRS
Equity (owners)	¥1.13T	at 2023-12-31	Cons.	Equity attributable to owners of parent IFRS
Equity (owners)	¥980.0bn	at 2022-12-31^d	Cons.	Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)	¥894.2bn	at 2021-12-31^d	Cons.	Equity attributable to owners of parent IFRS (5-year summary)
Equity (owners)	¥838.6bn	at 2020-12-31^d	Cons.	Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents	¥118.6bn	at 2024-12-31	Cons.	Cash and cash equivalents IFRS
Cash & equivalents	¥131.4bn	at 2023-12-31	Cons.	Cash and cash equivalents IFRS
Cash & equivalents	¥88.1bn	at 2022-12-31^d	Cons.	Cash and cash equivalents IFRS
Cash & equivalents	¥149.5bn	at 2021-12-31^d	Cons.	Cash and cash equivalents IFRS (5-year summary)
Cash & equivalents	¥161.7bn	at 2020-12-31^d	Cons.	Cash and cash equivalents IFRS (5-year summary)
Operating cash flow	¥242.8bn	2024-01-01 → 2024-12-31	Cons.	Net cash provided by used in operating activities IFRS
Operating cash flow	¥203.2bn	2023-01-01 → 2023-12-31	Cons.	Net cash provided by used in operating activities IFRS
Operating cash flow	¥135.6bn	2022-01-01 → 2022-12-31^d	Cons.	Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow	¥219.3bn	2021-01-01 → 2021-12-31^d	Cons.	Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow	¥164.8bn	2020-01-01 → 2020-12-31^d	Cons.	Cash flows from used in operating activities IFRS (5-year summary)
Investing cash flow	−¥329.4bn	2024-01-01 → 2024-12-31	Cons.	Net cash provided by used in investing activities IFRS
Investing cash flow	−¥226.1bn	2023-01-01 → 2023-12-31	Cons.	Net cash provided by used in investing activities IFRS
Investing cash flow	−¥10.4bn	2022-01-01 → 2022-12-31^d	Cons.	Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow	−¥56.4bn	2021-01-01 → 2021-12-31^d	Cons.	Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow	−¥116.0bn	2020-01-01 → 2020-12-31^d	Cons.	Cash flows from used in investing activities IFRS (5-year summary)
Financing cash flow	¥58.1bn	2024-01-01 → 2024-12-31	Cons.	Net cash provided by used in financing activities IFRS
Financing cash flow	¥35.9bn	2023-01-01 → 2023-12-31	Cons.	Net cash provided by used in financing activities IFRS
Financing cash flow	−¥167.8bn	2022-01-01 → 2022-12-31^d	Cons.	Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow	−¥180.5bn	2021-01-01 → 2021-12-31^d	Cons.	Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow	−¥52.5bn	2020-01-01 → 2020-12-31^d	Cons.	Cash flows from used in financing activities IFRS (5-year summary)
EPS (basic)	¥71.87	2024-01-01 → 2024-12-31	Cons.	Basic earnings loss per share IFRS
EPS (basic)	¥139.16	2023-01-01 → 2023-12-31	Cons.	Basic earnings loss per share IFRS
EPS (basic)	¥135.08	2022-01-01 → 2022-12-31^d	Cons.	Basic earnings loss per share IFRS (5-year summary)
EPS (basic)	¥71.73	2021-01-01 → 2021-12-31^d	Cons.	Basic earnings loss per share IFRS (5-year summary)
EPS (basic)	¥85.57	2020-01-01 → 2020-12-31^d	Cons.	Basic earnings loss per share IFRS (5-year summary)
EPS (diluted)	¥71.86	2024-01-01 → 2024-12-31	Cons.	Diluted earnings loss per share IFRS
EPS (diluted)	¥139.15	2023-01-01 → 2023-12-31	Cons.	Diluted earnings loss per share IFRS
EPS (diluted)	¥135.07	2022-01-01 → 2022-12-31^d	Cons.	Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)	¥71.7	2021-01-01 → 2021-12-31^d	Cons.	Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)	¥85.54	2020-01-01 → 2020-12-31^d	Cons.	Diluted earnings loss per share IFRS (5-year summary)
Net assets per share	¥1,458.68	at 2024-12-31	Cons.	Equity to asset ratio IFRS (5-year summary)
Net assets per share	¥1,398.47	at 2023-12-31	Cons.	Equity to asset ratio IFRS (5-year summary)
Net assets per share	¥1,210.16	at 2022-12-31^d	Cons.	Equity to asset ratio IFRS (5-year summary)
Net assets per share	¥1,072.69	at 2021-12-31^d	Cons.	Equity to asset ratio IFRS (5-year summary)
Net assets per share	¥1,005.96	at 2020-12-31^d	Cons.	Equity to asset ratio IFRS (5-year summary)
Equity ratio	35.2%	at 2024-12-31	Cons.	Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio	39.5%	at 2023-12-31	Cons.	Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio	38.5%	at 2022-12-31^d	Cons.	Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio	36.2%	at 2021-12-31^d	Cons.	Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio	34.1%	at 2020-12-31^d	Cons.	Ratio of owners equity to gross assets IFRS (5-year summary)
ROE	5.0%	2024-01-01 → 2024-12-31	Cons.	Rate of return on equity IFRS (5-year summary)
ROE	10.7%	2023-01-01 → 2023-12-31	Cons.	Rate of return on equity IFRS (5-year summary)
ROE	11.8%	2022-01-01 → 2022-12-31^d	Cons.	Rate of return on equity IFRS (5-year summary)
ROE	6.9%	2021-01-01 → 2021-12-31^d	Cons.	Rate of return on equity IFRS (5-year summary)
ROE	8.2%	2020-01-01 → 2020-12-31^d	Cons.	Rate of return on equity IFRS (5-year summary)
Employees	31,934	at 2024-12-31	Cons.	Number of employees
Revenue	¥194.6bn	2024-01-01 → 2024-12-31	Standalone	Operating revenue1
Revenue	¥139.0bn	2023-01-01 → 2023-12-31	Standalone	Operating revenue1
Revenue	¥152.8bn	2022-01-01 → 2022-12-31^d	Standalone	Net sales (5-year summary)
Revenue	¥139.5bn	2021-01-01 → 2021-12-31^d	Standalone	Net sales (5-year summary)
Revenue	¥138.8bn	2020-01-01 → 2020-12-31^d	Standalone	Net sales (5-year summary)
Operating income	¥114.5bn	2024-01-01 → 2024-12-31	Standalone	Operating income
Operating income	¥64.4bn	2023-01-01 → 2023-12-31	Standalone	Operating income
Ordinary income	¥60.4bn	2024-01-01 → 2024-12-31	Standalone	Ordinary income
Ordinary income	¥62.2bn	2023-01-01 → 2023-12-31	Standalone	Ordinary income
Ordinary income	¥76.9bn	2022-01-01 → 2022-12-31^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥73.8bn	2021-01-01 → 2021-12-31^d	Standalone	Ordinary income loss (5-year summary)
Ordinary income	¥72.0bn	2020-01-01 → 2020-12-31^d	Standalone	Ordinary income loss (5-year summary)
Profit before tax	−¥332.2bn	2024-01-01 → 2024-12-31	Standalone	Income before income taxes
Profit before tax	¥77.2bn	2023-01-01 → 2023-12-31	Standalone	Income before income taxes
Net income	−¥344.9bn	2024-01-01 → 2024-12-31	Standalone	Profit loss
Net income	¥70.4bn	2023-01-01 → 2023-12-31	Standalone	Profit loss
Net income	¥48.7bn	2022-01-01 → 2022-12-31^d	Standalone	Net income loss (5-year summary)
Net income	¥77.3bn	2021-01-01 → 2021-12-31^d	Standalone	Net income loss (5-year summary)
Net income	¥79.3bn	2020-01-01 → 2020-12-31^d	Standalone	Net income loss (5-year summary)
Total assets	¥1.85T	at 2024-12-31	Standalone	Assets
Total assets	¥2.28T	at 2023-12-31	Standalone	Assets
Total assets	¥1.90T	at 2022-12-31^d	Standalone	Total assets (5-year summary)
Total assets	¥2.00T	at 2021-12-31^d	Standalone	Total assets (5-year summary)
Total assets	¥1.97T	at 2020-12-31^d	Standalone	Total assets (5-year summary)
Total liabilities	¥1.29T	at 2024-12-31	Standalone	Liabilities
Total liabilities	¥1.32T	at 2023-12-31	Standalone	Liabilities
Net assets / equity	¥561.9bn	at 2024-12-31	Standalone	Net assets
Net assets / equity	¥964.2bn	at 2023-12-31	Standalone	Net assets
Net assets / equity	¥951.1bn	at 2022-12-31^d	Standalone	Net assets
Net assets / equity	¥1.01T	at 2021-12-31^d	Standalone	Net assets (5-year summary)
Net assets / equity	¥987.1bn	at 2020-12-31^d	Standalone	Net assets (5-year summary)
Cash and deposits	¥12.2bn	at 2024-12-31	Standalone	Cash and deposits
Cash and deposits	¥20.2bn	at 2023-12-31	Standalone	Cash and deposits
EPS (basic)	¥-425.84	2024-01-01 → 2024-12-31	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥86.91	2023-01-01 → 2023-12-31	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥59.24	2022-01-01 → 2022-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥92.67	2021-01-01 → 2021-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
EPS (basic)	¥94.37	2020-01-01 → 2020-12-31^d	Standalone	Basic earnings loss per share (5-year summary)
Dividend per share	¥71	2024-01-01 → 2024-12-31	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥71	2023-01-01 → 2023-12-31	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥69	2022-01-01 → 2022-12-31^d	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥65	2021-01-01 → 2021-12-31^d	Standalone	Dividend paid per share (5-year summary)
Dividend per share	¥65	2020-01-01 → 2020-12-31^d	Standalone	Dividend paid per share (5-year summary)
Net assets per share	¥693.7	at 2024-12-31	Standalone	Net assets per share (5-year summary)
Net assets per share	¥1,190.61	at 2023-12-31	Standalone	Net assets per share (5-year summary)
Net assets per share	¥1,174.47	at 2022-12-31^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥1,208.06	at 2021-12-31^d	Standalone	Net assets per share (5-year summary)
Net assets per share	¥1,184.06	at 2020-12-31^d	Standalone	Net assets per share (5-year summary)
Equity ratio	30.4%	at 2024-12-31	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	42.3%	at 2023-12-31	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	50.1%	at 2022-12-31^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	50.4%	at 2021-12-31^d	Standalone	Equity to asset ratio (5-year summary)
Equity ratio	50.1%	at 2020-12-31^d	Standalone	Equity to asset ratio (5-year summary)
ROE	-45.2%	2024-01-01 → 2024-12-31	Standalone	Rate of return on equity (5-year summary)
ROE	7.3%	2023-01-01 → 2023-12-31	Standalone	Rate of return on equity (5-year summary)
ROE	5.0%	2022-01-01 → 2022-12-31^d	Standalone	Rate of return on equity (5-year summary)
ROE	7.8%	2021-01-01 → 2021-12-31^d	Standalone	Rate of return on equity (5-year summary)
ROE	7.8%	2020-01-01 → 2020-12-31^d	Standalone	Rate of return on equity (5-year summary)
Shares issued	914,000,000	at 2024-12-31	Standalone	Total number of issued shares (5-year summary)
Shares issued	914,000,000	at 2023-12-31	Standalone	Total number of issued shares (5-year summary)
Shares issued	914,000,000	at 2022-12-31^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	914,000,000	at 2021-12-31^d	Standalone	Total number of issued shares (5-year summary)
Shares issued	914,000,000	at 2020-12-31^d	Standalone	Total number of issued shares (5-year summary)
Employees	1,067	at 2024-12-31	Standalone	Number of employees
Employees	977	at 2023-12-31	Standalone	Number of employees
Employees	914	at 2022-12-31^d	Standalone	Number of employees
Employees	1,156	at 2021-12-31^d	Standalone	Number of employees
Employees	1,117	at 2020-12-31^d	Standalone	Number of employees

Periods use the dates stated in the filing. ^d = earlier-year period dated by calendar; ^v = that date confirmed by the company's own earlier filing.

Segments · 75

Segment	Item	Period	Value
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	capex	2024-01-01 → 2024-12-31	¥7.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	employees	at 2024-12-31	2113 pure
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	revenue	2024-01-01 → 2024-12-31	¥97.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	revenue external	2024-01-01 → 2024-12-31	¥21.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	revenue intersegment	2024-01-01 → 2024-12-31	¥76.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	segment assets	at 2024-12-31	¥362.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	segment profit	2024-01-01 → 2024-12-31	¥30m
Reconciling Itemsreconciling	capex	2024-01-01 → 2024-12-31	¥10.4bn
Reconciling Itemsreconciling	revenue	2024-01-01 → 2024-12-31	−¥86.4bn
Reconciling Itemsreconciling	revenue intersegment	2024-01-01 → 2024-12-31	−¥86.4bn
Reconciling Itemsreconciling	segment assets	at 2024-12-31	−¥478.8bn
Reconciling Itemsreconciling	segment profit	2024-01-01 → 2024-12-31	−¥58.0bn
Alcoholic Beveragesreportable segment	capex	2024-01-01 → 2024-12-31	¥39.0bn
Alcoholic Beveragesreportable segment	employees	at 2024-12-31	8925 pure
Alcoholic Beveragesreportable segment	revenue	2024-01-01 → 2024-12-31	¥1.08T
Alcoholic Beveragesreportable segment	revenue external	2024-01-01 → 2024-12-31	¥1.08T
Alcoholic Beveragesreportable segment	revenue intersegment	2024-01-01 → 2024-12-31	¥2.3bn
Alcoholic Beveragesreportable segment	segment assets	at 2024-12-31	¥1.37T
Alcoholic Beveragesreportable segment	segment profit	2024-01-01 → 2024-12-31	¥124.0bn
Health Sciencereportable segment	capex	2024-01-01 → 2024-12-31	¥6.7bn
Health Sciencereportable segment	employees	at 2024-12-31	5954 pure
Health Sciencereportable segment	revenue	2024-01-01 → 2024-12-31	¥179.5bn
Health Sciencereportable segment	revenue external	2024-01-01 → 2024-12-31	¥175.3bn
Health Sciencereportable segment	revenue intersegment	2024-01-01 → 2024-12-31	¥4.2bn
Health Sciencereportable segment	segment assets	at 2024-12-31	¥764.1bn
Health Sciencereportable segment	segment profit	2024-01-01 → 2024-12-31	−¥10.9bn
Non Alcoholic Beveragesreportable segment	capex	2024-01-01 → 2024-12-31	¥20.9bn
Non Alcoholic Beveragesreportable segment	employees	at 2024-12-31	7887 pure
Non Alcoholic Beveragesreportable segment	revenue	2024-01-01 → 2024-12-31	¥567.8bn
Non Alcoholic Beveragesreportable segment	revenue external	2024-01-01 → 2024-12-31	¥564.9bn
Non Alcoholic Beveragesreportable segment	revenue intersegment	2024-01-01 → 2024-12-31	¥3.0bn
Non Alcoholic Beveragesreportable segment	segment assets	at 2024-12-31	¥326.4bn
Non Alcoholic Beveragesreportable segment	segment profit	2024-01-01 → 2024-12-31	¥64.0bn
Pharmaceuticalsreportable segment	capex	2024-01-01 → 2024-12-31	¥109.5bn
Pharmaceuticalsreportable segment	employees	at 2024-12-31	5669 pure
Pharmaceuticalsreportable segment	revenue	2024-01-01 → 2024-12-31	¥495.6bn
Pharmaceuticalsreportable segment	revenue external	2024-01-01 → 2024-12-31	¥495.3bn
Pharmaceuticalsreportable segment	revenue intersegment	2024-01-01 → 2024-12-31	¥264m
Pharmaceuticalsreportable segment	segment assets	at 2024-12-31	¥1.01T
Pharmaceuticalsreportable segment	segment profit	2024-01-01 → 2024-12-31	¥91.9bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	capex	2023-01-01 → 2023-12-31	¥2.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	revenue	2023-01-01 → 2023-12-31	¥94.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	revenue external	2023-01-01 → 2023-12-31	¥27.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	revenue intersegment	2023-01-01 → 2023-12-31	¥66.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	segment assets	at 2023-12-31	¥510.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments	segment profit	2023-01-01 → 2023-12-31	−¥60m
Reconciling Itemsreconciling	capex	2023-01-01 → 2023-12-31	¥10.3bn
Reconciling Itemsreconciling	revenue	2023-01-01 → 2023-12-31	−¥76.4bn
Reconciling Itemsreconciling	revenue intersegment	2023-01-01 → 2023-12-31	−¥76.4bn
Reconciling Itemsreconciling	segment assets	at 2023-12-31	−¥719.8bn
Reconciling Itemsreconciling	segment profit	2023-01-01 → 2023-12-31	−¥54.2bn
Alcoholic Beveragesreportable segment	capex	2023-01-01 → 2023-12-31	¥39.1bn
Alcoholic Beveragesreportable segment	revenue	2023-01-01 → 2023-12-31	¥1.05T
Alcoholic Beveragesreportable segment	revenue external	2023-01-01 → 2023-12-31	¥1.05T
Alcoholic Beveragesreportable segment	revenue intersegment	2023-01-01 → 2023-12-31	¥2.3bn
Alcoholic Beveragesreportable segment	segment assets	at 2023-12-31	¥1.35T
Alcoholic Beveragesreportable segment	segment profit	2023-01-01 → 2023-12-31	¥119.9bn
Health Sciencereportable segment	capex	2023-01-01 → 2023-12-31	¥10.1bn
Health Sciencereportable segment	revenue	2023-01-01 → 2023-12-31	¥108.0bn
Health Sciencereportable segment	revenue external	2023-01-01 → 2023-12-31	¥103.4bn
Health Sciencereportable segment	revenue intersegment	2023-01-01 → 2023-12-31	¥4.7bn
Health Sciencereportable segment	segment assets	at 2023-12-31	¥473.7bn
Health Sciencereportable segment	segment profit	2023-01-01 → 2023-12-31	−¥12.5bn
Non Alcoholic Beveragesreportable segment	capex	2023-01-01 → 2023-12-31	¥24.2bn
Non Alcoholic Beveragesreportable segment	revenue	2023-01-01 → 2023-12-31	¥518.9bn
Non Alcoholic Beveragesreportable segment	revenue external	2023-01-01 → 2023-12-31	¥516.2bn
Non Alcoholic Beveragesreportable segment	revenue intersegment	2023-01-01 → 2023-12-31	¥2.8bn
Non Alcoholic Beveragesreportable segment	segment assets	at 2023-12-31	¥287.4bn
Non Alcoholic Beveragesreportable segment	segment profit	2023-01-01 → 2023-12-31	¥52.4bn
Pharmaceuticalsreportable segment	capex	2023-01-01 → 2023-12-31	¥33.3bn
Pharmaceuticalsreportable segment	revenue	2023-01-01 → 2023-12-31	¥442.2bn
Pharmaceuticalsreportable segment	revenue external	2023-01-01 → 2023-12-31	¥441.9bn
Pharmaceuticalsreportable segment	revenue intersegment	2023-01-01 → 2023-12-31	¥351m
Pharmaceuticalsreportable segment	segment assets	at 2023-12-31	¥971.4bn
Pharmaceuticalsreportable segment	segment profit	2023-01-01 → 2023-12-31	¥96.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 2,393

Item	Context	Value	Unit
Net assets	CurrentYearInstant_NonConsolidatedMember	561893000000	JPY
Liabilities and net assets	Prior1YearInstant_NonConsolidatedMember	2282080000000	JPY
Liabilities and net assets	CurrentYearInstant_NonConsolidatedMember	1847181000000	JPY
Group management revenue rev oa	Prior1YearDuration_NonConsolidatedMember	58088000000	JPY
Group management revenue rev oa	CurrentYearDuration_NonConsolidatedMember	63586000000	JPY
Dividends revenue from subsidiaries and affiliates rev oa	Prior1YearDuration_NonConsolidatedMember	66969000000	JPY
Dividends revenue from subsidiaries and affiliates rev oa	CurrentYearDuration_NonConsolidatedMember	116410000000	JPY
Other income rev oa	Prior1YearDuration_NonConsolidatedMember	13973000000	JPY
Other income rev oa	CurrentYearDuration_NonConsolidatedMember	14605000000	JPY
Operating revenue1	Prior1YearDuration_NonConsolidatedMember	139030000000	JPY
Operating revenue1	CurrentYearDuration_NonConsolidatedMember	194601000000	JPY
General and administrative expenses sga	Prior1YearDuration_NonConsolidatedMember	67408000000	JPY
General and administrative expenses sga	CurrentYearDuration_NonConsolidatedMember	72745000000	JPY
Other sga	Prior1YearDuration_NonConsolidatedMember	7193000000	JPY
Other sga	CurrentYearDuration_NonConsolidatedMember	7385000000	JPY
Operating expenses	Prior1YearDuration_NonConsolidatedMember	74601000000	JPY
Operating expenses	CurrentYearDuration_NonConsolidatedMember	80130000000	JPY
Operating income	Prior1YearDuration_NonConsolidatedMember	64429000000	JPY
Operating income	CurrentYearDuration_NonConsolidatedMember	114471000000	JPY
Interest and dividends income noi	Prior1YearDuration_NonConsolidatedMember	4454000000	JPY
Interest and dividends income noi	CurrentYearDuration_NonConsolidatedMember	12424000000	JPY
Foreign exchange gains noi	Prior1YearDuration_NonConsolidatedMember	1506000000	JPY
Foreign exchange gains noi	CurrentYearDuration_NonConsolidatedMember	1123000000	JPY
Other noi	Prior1YearDuration_NonConsolidatedMember	1733000000	JPY
Other noi	CurrentYearDuration_NonConsolidatedMember	2657000000	JPY
Non operating income	Prior1YearDuration_NonConsolidatedMember	7692000000	JPY
Non operating income	CurrentYearDuration_NonConsolidatedMember	16203000000	JPY
Interest expenses noe	Prior1YearDuration_NonConsolidatedMember	4510000000	JPY
Interest expenses noe	CurrentYearDuration_NonConsolidatedMember	15887000000	JPY
Provision of allowance for doubtful accounts noe	Prior1YearDuration_NonConsolidatedMember	3914000000	JPY
Provision of allowance for doubtful accounts noe	CurrentYearDuration_NonConsolidatedMember	52438000000	JPY
Other noe	Prior1YearDuration_NonConsolidatedMember	1458000000	JPY
Other noe	CurrentYearDuration_NonConsolidatedMember	1948000000	JPY
Non operating expenses	Prior1YearDuration_NonConsolidatedMember	9881000000	JPY
Non operating expenses	CurrentYearDuration_NonConsolidatedMember	70273000000	JPY
Ordinary income	Prior1YearDuration_NonConsolidatedMember	62239000000	JPY
Ordinary income	CurrentYearDuration_NonConsolidatedMember	60401000000	JPY
Gain on sales of noncurrent assets ei	Prior1YearDuration_NonConsolidatedMember	1112000000	JPY
Gain on sales of noncurrent assets ei	CurrentYearDuration_NonConsolidatedMember	885000000	JPY
Gain on sales of subsidiaries and affiliates stocks ei	Prior1YearDuration_NonConsolidatedMember	14454000000	JPY
Gain on sales of subsidiaries and affiliates stocks ei	CurrentYearDuration_NonConsolidatedMember	－	JPY
Compensation income ei	Prior1YearDuration_NonConsolidatedMember	－	JPY
Compensation income ei	CurrentYearDuration_NonConsolidatedMember	1918000000	JPY
Other ei	Prior1YearDuration_NonConsolidatedMember	－	JPY
Other ei	CurrentYearDuration_NonConsolidatedMember	18000000	JPY
Extraordinary income	Prior1YearDuration_NonConsolidatedMember	15567000000	JPY
Extraordinary income	CurrentYearDuration_NonConsolidatedMember	2822000000	JPY
Loss on sales and retirement of noncurrent assets el	Prior1YearDuration_NonConsolidatedMember	432000000	JPY
Loss on sales and retirement of noncurrent assets el	CurrentYearDuration_NonConsolidatedMember	192000000	JPY
Loss on valuation of stocks of subsidiaries and affiliates el	Prior1YearDuration_NonConsolidatedMember	－	JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 21 of 21 passed

balance sheet identity	consolidated 2023-12-31	pass
balance sheet identity	consolidated 2024-12-31	pass
balance sheet identity	non_consolidated 2023-12-31	pass
balance sheet identity	non_consolidated 2024-12-31	pass
dei present		pass
period resolution		pass
statement vs summary · net assets	non_consolidated 2022-12-31	pass
statement vs summary · net assets	non_consolidated 2023-12-31	pass
statement vs summary · net assets	non_consolidated 2024-12-31	pass
statement vs summary · net income attributable to parent	consolidated 2023-01-01/2023-12-31	pass
statement vs summary · net income attributable to parent	consolidated 2024-01-01/2024-12-31	pass
statement vs summary · operating cash flow	consolidated 2023-01-01/2023-12-31	pass
statement vs summary · operating cash flow	consolidated 2024-01-01/2024-12-31	pass
statement vs summary · revenue	consolidated 2023-01-01/2023-12-31	pass
statement vs summary · revenue	consolidated 2024-01-01/2024-12-31	pass
statement vs summary · revenue	non_consolidated 2023-01-01/2023-12-31	pass
statement vs summary · revenue	non_consolidated 2024-01-01/2024-12-31	pass
statement vs summary · total assets	consolidated 2023-12-31	pass
statement vs summary · total assets	consolidated 2024-12-31	pass
statement vs summary · total assets	non_consolidated 2023-12-31	pass
statement vs summary · total assets	non_consolidated 2024-12-31	pass